| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 42238-0111-12 | 42238-0111 | Interferon gamma-1b | Actimmune | 100.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Dec 1, 2013 | Jan 17, 2018 | No Longer Used |
| 00469-4425-30 | 00469-4425 | ZOLBETUXIMAB | VYLOY | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CLDN18.2 | Intravenous | Apr 24, 2025 | In Use | |
| 00024-0674-01 | 00024-0674 | Isatuximab-irfc | Sarclisa Escena | 140.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD38 | Subcutaneous | Jul 9, 2026 | In Use | |
| 47781-0484-28 | 47781-0484 | Lenalidomide | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 3, 2022 | In Use | |
| 00003-2327-11 | 00003-2327 | Ipilimumab | Yervoy | 5.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | Intravenous | Mar 25, 2011 | In Use | |
| 70095-0058-01 | 70095-0058 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Aug 31, 2026 | In Use | |
| 55513-0954-21 | 55513-0954 | Panitumumab | Vectibix | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 1, 2025 | In Use | |
| 59651-0346-07 | 59651-0346 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 59651-0343-07 | 59651-0343 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 63459-0305-47 | 63459-0305 | TRASTUZUMAB | HERZUMA | Immunotherapy | Monoclonal Antibody | HER2 | Mar 16, 2020 | In Use | |||
| 00378-1941-21 | 00378-1941 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 00006-5083-01 | 00006-5083 | Pembrolizumab and berahyaluronidase alfa-pmph | KEYTRUDA QLEX | 2000.0 U/mL, 165.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Sep 19, 2025 | In Use | |
| 54868-4554-01 | 54868-4554 | Imiquimod | Aldara | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Jun 19, 2003 | Sep 30, 2009 | No Longer Used | |
| 31722-0261-21 | 31722-0261 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 82293-0010-10 | 82293-0010 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 6, 2026 | In Use | |
| 50242-0103-01 | 50242-0103 | polatuzumab vedotin | POLIVY | 30.0 mg/1.88mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | Sep 18, 2020 | In Use | |
| 70771-1677-01 | 70771-1677 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
| 80739-0812-18 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec 12, 2022 | In Use | |
| 63459-0303-43 | 63459-0303 | TRASTUZUMAB | HERZUMA | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Mar 16, 2020 | In Use | |
| 31722-0770-32 | 31722-0770 | Pomalidomide | Pomalidomide | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 42747-0761-01 | 42747-0761 | mogamulizumab-kpkc | POTELIGEO | 4.0 mg/mL | Immunotherapy | Monoclonal Antibody | CCR4 | Intravenous | Aug 8, 2018 | In Use | |
| 31722-0772-32 | 31722-0772 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 31722-0771-01 | 31722-0771 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 73043-0039-28 | 73043-0039 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 31, 2026 | In Use | |
| 00781-7152-09 | 00781-7152 | Imiquimod | Imiquimod | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb 28, 2011 | May 31, 2014 | No Longer Used |
Found 12611 results — Export these results
Home